Placeholder Banner

Influential CEO Jamie Dimon to Deliver Keynote at BIO 2019

April 29, 2019
Media Contact
Theresa Brady

Washington, D.C. (April 29, 2019) – The Biotechnology Innovation Organization (BIO) today announced that Chairman and CEO of JPMorgan Chase & Co., Jamie Dimon – a leader in the banking industry and catalyst for innovation across American business, including the healthcare industry– will headline a keynote address at the 2019 BIO International Convention, the world’s premier life sciences event being held in Philadelphia, June 3-6.

Dimon leads one of the oldest financial institutions in the U.S., with a history dating back over 200 years, a presence in over 100 markets, and over 250,000 employees. The firm has assets of $2.7 trillion and serves millions of customers in the U.S. and many of the world's most prominent corporate, institutional and government clients. At the helm, Dimon has led the launch of novel strategies to address diversity and healthcare challenges, including Advancing Black Leaders and Women on the Move initiatives, and a recent partnership with Amazon and Berkshire Hathaway to launch Haven, an independent company designed to address healthcare for their U.S. employees and reduce associated costs. His company has also launched AdvancingCities, a new $500 million, five-year initiative to drive inclusive growth and create greater economic opportunity in cities across the world.

“We are inspired by Jamie’s successful leadership of the world’s largest banking institution and look forward to his views on ways in which small, innovative companies can position themselves in the global economy,” said Jim Greenwood, President and Chief Executive Officer of BIO. “His innovative strategies for improving employee satisfaction, and commitment to cultivating a new generation of diverse leadership are an inspiration to the biotech community as we work to take actionable steps toward a more diversified and inclusive industry.”

Dimon will address attendees on Wednesday, June 5, 2019 at the keynote session from 9:00-10:30AM (EST). The session is sponsored by Alnylam Pharmaceuticals and is open to attendees with Convention Access or higher.

BIO 2019 is expected to attract over 16,000 attendees and 1,800 exhibitors from 67 countries. Complimentary media registration is available to editors and reporters working full time for print, broadcast or web publications with valid press credentials.

About Jamie Dimon

Named four times to Time Magazine's TIME 100 most influential people in the world list and Fortune’s World’s Greatest Leaders for 2018 list, James Dimon became Chairman of the Board of JPMorgan Chase & Co. (NYSE: JPM) in 2006, and has been Chief Executive Officer and President since December 31, 2005. He was President and Chief Operating Officer following JPMorgan Chase’s merger with Bank One Corporation in July 2004. At Bank One, he was Chairman and Chief Executive Officer from March 2000 to July 2004. Before joining Bank One, Mr. Dimon held a wide range of executive roles at Citigroup Inc., the Travelers Group, Commercial Credit Company and American Express Company. He is on the Board of Directors of Harvard Business School and Catalyst; Board of Trustees of New York University School of Medicine Chairman of the Business Roundtable; and a member of The Business Council. He has served on the board of directors of the Federal Reserve Bank of New York and does not serve on the board of any publicly traded company other than JPMorgan Chase. Mr. Dimon graduated from Tufts University and received an M.B.A. from Harvard Business School.


Discover More
Public opinion polls show there is significant mistrust among the American public in the safety and efficacy of vaccines. So today, the Biotechnology…
The Biotechnology Innovation Organization (BIO), the California Life Sciences Association (CLSA), and BIOCOM California today filed a challenge against the Department of Health and Human Services’ (HHS) attempt, during the final days of the Trump…
Washington, DC (December 2, 2020) - Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement regarding Nasdaq's filing with the Securities and Exchange Commission…